Nexeon™ AVX Decellularized Femoral Artery

The purpose of this study is to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon™ AVX Decellularized Femoral Artery, LifeNet Health, Virginia Beach, VA) used in the creation of vascular access for hemodialysis in patients with ESRD (End Stage Renal Disease).

For more information about this study, including how to volunteer, contact:

Sara Niesobecki

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

Eligibility Criteria

Be male or female, ≥18 years of age at the time of graft placement.
Have a diagnosis of ESRD or renal dysfunction requiring hemodialysis.
Require dialysis access to start or maintain dialysis treatment, with placement of an AV access graft being a viable option.
Have the ability, either personally or through a legal guardian, to understand the study requirements, provide written informed consent/assent as evidenced by signature on an IRB-approved informed consent form (ICF), and agree to abide by study restrictions and return for required assessments.
Have provided written authorization for use and disclosure of protected health information.